文献速递浆细胞疾病造血干细胞移植与细胞治疗

Letetresgene autoleucel单用或联合帕博利珠单抗治疗复发/难治性多发性骨髓瘤的安全性与疗效

Safety and efficacy of letetresgene autoleucel alone or with pembrolizumab for relapsed/refractory multiple myeloma.
PubMed 文献 · Blood Adv · 2023-01-01

这项先导研究评估了靶向NY-ESO-1/LAGE-1a的基因修饰自体T细胞疗法lete-cel单用或联合帕博利珠单抗治疗复发/难治性多发性骨髓瘤。127例患者筛查后仅6例(每组3例)入组,所有患者出现3/4级血细胞减少,合并总体缓解率为50%,无进展生存期为1.3至5.2个月,lete-cel安全性可控并显示出明确但短暂的抗肿瘤活性。

要点

  • 所有6例患者均出现3/4级血细胞减少,后缓解或改善至1级。
  • 合并总体缓解率为50%,缓解者至缓解时间3周,缓解持续时间2.1个月。
  • 无进展生存期为1.3至5.2个月,lete-cel显示出明确但短暂的抗肿瘤活性。

核心结论

  • Lete-cel安全性可控,在复发/难治性多发性骨髓瘤患者中显示出明确但短暂的抗肿瘤活性。

研究设计与样本

  • 先导研究,评估lete-cel单用(第1组)或联合帕博利珠单抗(第2组)治疗复发/难治性多发性骨髓瘤。
  • 127例患者接受筛查,6例患者入组(每组3例),入组患者表达NY-ESO-1和/或LAGE-1a且为HLA-A*02:01、*02:05或*02:06。
  • 试验注册号为NCT03168438。

主要发现

  • 所有患者出现3/4级血细胞减少,均缓解或改善至1级。
  • 第1组1例患者出现3/4级lete-cel相关不良事件;第2组2例患者出现与lete-cel及淋巴细胞清除相关的3/4级不良事件。
  • 3例1/2级细胞因子释放综合征(CRS)患者lete-cel输注后白细胞介素-6水平高于无CRS者。
  • 合并总体缓解率为50%,包括确认的临床缓解、非常好的临床缓解和部分缓解各1例;无进展生存期为1.3至5.2个月。
  • 缓解者(第1组n=1;第2组n=2)至缓解时间为3周,缓解持续时间为2.1个月;2例缓解者(无未缓解者)lete-cel输注后细胞因子水平升高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This pilot study assessed the safety and efficacy of letetresgene autoleucel (lete-cel; GSK3377794), a genetically modified autologous T-cell therapy targeting New York esophageal squamous cell carcinoma-1 (NY-ESO-1)/L antigen family member 1 isoform A (LAGE-1a)-positive myeloma cells, alone or in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma. Eligible patients expressed NY-ESO-1 and/or LAGE-1a and either HLA-A∗02:01, ∗02:05, or ∗02:06. Patients received lete-cel single infusion alone (arm 1) or with pembrolizumab (arm 2). 127 patients were screened, and 6 patients (3 per arm) were enrolled; patients in arm 1 and 2 received lete-cel alone, or with pembrolizumab, respectively. All patients exhibited grade 3/4 cytopenias, which resolved or improved to grade 1. One patient (arm 1) had grade 3/4 lete-cel-related adverse events (AEs); 2 patients (arm 2) had grade 3/4 AEs related to lete-cel and lymphodepletion. Three patients with grade 1/2 cytokine release syndrome (CRS) exhibited elevated post-lete-cel interleukin-6 levels versus those without CRS. Pooled overall response rate was 50% including 1 patient each with confirmed clinical response, very good clinical response, and partial response, and progression-free survival ranged from 1.3 to 5.2 months. Responders (arm 1: n = 1; arm 2: n = 2) had a time-to-response of 3 weeks, duration of response of 2.1 months. Two responders, but no nonresponders, exhibited elevated cytokine levels after lete-cel infusion. Lete-cel had a manageable safety profile and demonstrated clear but transient antitumor activity in patients with relapsed/refractory multiple myeloma. This trial was registered at www.clinicaltrials.gov as #NCT03168438.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Nishihori T, Hoffman JE, Huff A, et al. Safety and efficacy of letetresgene autoleucel alone or with pembrolizumab for relapsed/refractory multiple myeloma. Blood Adv. 2023. PMID: 36534160. doi:10.1182/bloodadvances.2022008460

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。